|Day Low/High||50.19 / 52.57|
|52 Wk Low/High||30.15 / 64.94|
Pacific Biosciences of California, AMAG Pharmaceuticals and Global Blood Therapeutics were among the biotech stock movers in premarket trading on Tuesday.
You can feel the misery of those who are struggling with feelings of being left behind.
Its members are skeptical about the market celebration and are not going to commit to a course of rate hikes until they have more data.
If the indices take out yesterday's lows I'll be very bearish very quickly.
Good picks make it easier to produce good results, but they are just a starting point.
Investors in Global Blood Therapeutics Inc saw new options become available this week, for the January 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GBT options chain for the new January 2017 contracts and identified one put and one call contract of particular interest.
I spent the weekend with thousands of blood disease researchers. This is what happened.
The market isn't buying that Trump is bad for business
The American Society of Hematology (ASH) annual meeting is one of the most important medical conferences held each year, focusing on new drugs to treat blood-related diseases, including blood cancers.
Such unwarranted fears have depressed the sector, which could bounce back after Nov. 8.
Global Blood wants to start screening sickle cell disease patients for the phase III study in December with the hope of having top-line results in the first half of 2019.
Data Presented at 10th Anniversary Conference of Academy for Sickle Cell and Thalassemia (ASCAT)
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.